anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This invention refers to the production of erythromycin A derivatives,  in particular to the production of 9 _ oxime erythro¬¬¬mycin A derivatives used as antiseptics or semiconductor for its synthesis.    Technical result is to provide new semifinished products for synthesis of 6 _ 0 _ methyl derivatives of erythromycin.  The compound of formula II are used for the production of the compounds of the general formula I :       in which R1 _ C1 _ C3 alkyl benzil ( it can be substituted by methoxy,  NO2 , mono or dihaloid ); naphtylmethyl, used as antiseptic or semifinished product for its synthesis.    Technical result is to provide new semifinished products for synthesis of 6 _ 0 _ methyl derivatives of erythromycin.     Besides, the use of new 9 _ oxime derivatives allows to increase selectivity of the production of 6 _ 0 _ methyl derivatives of erythromycin A, methylthiomethyl 1,2,2 trichlorethoxymethyl,  benzi¬lo¬¬ximethyl, benzhydril, R2 _ H, benziloxicarbonyl;    R5 _Ðmethyl benziloxicarbonyl, provided that R5  *  H, when R3 is methyl. The compound (II) is subjected to oximation by hydroxylamin in the presence of imidazol, at the molar proportion of 1 : 5 : 5,5 in the medium of methanol at room temperature duiring two days. Then the obtained substance is treated by haloid derivative of the formula III : R1 _ X, wherein X is halogen, in the presence of KOH or NaOH or sodium hydride at their molar proportion 1 : ( 1,08 _ 2 ) :        ( 0,93 _ 1,5 ) in the medium of aceton or tetrahydrofuran or dimethylphormamide at temperature range from room temperature to 00 C during period of 15 minutes _ two hours. Then the obtained substituted 9 _ oxim erythromycin is subjected to the reaction of iodine methyl or dimethylsulphate in the presence of KOH or NaOH at their molar proportion of 1 : ( 1* 5 ) :  ( 0,8 * 3 )  ( besides powder alkali only sodium hydrid can be used )  in the medium of solvent the _ mixture of dimethylsulphoxide with tetrahydrofuran or with 1,2 _ dimethoxiethanol or dimethylformamide at tempe¬ra¬ture at temperature from 00 C to room tempe¬ra¬¬ture during 40 minutes _ five hours. The obtained product allows to get selectively 6 _ 0 _ methyl derivatives of erythromycin A ( the yield up to 90,2 % against 80 % in the known method ).
Blood for pharmacokinetic analyses will be drawn prior to the first administration and immediately before administration at 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, and 11 hours. Thereafter samples will be drawn at 5, 10, 15, 20, 25, 30, 45, and 60 minutes after the 11-hour administration. Easiness of use will be rated using an 8-grade ordered category scale at 10 minutes after the start of administrations at 3, 6, and 9 hours. Overall liking will be rated using an 8-grade ordered category scale at 12 hours. Urges to smoke will be rated on a 4-grade ordered category scale immediately before and at 15 minutes after the first administration, and as well as before and 15 minutes after the start of administrations at 3, 6, and 9 hours, and at 12 hours. Used cartridges will be collected. Pooled samples per subject and treatment will be analyzed to determine the amount of remaining nicotine. Tolerability of the treatments will be evaluated in terms of reported and observed adverse events (AE).

Since the primary objective is to compare steady-state nicotine pharmacokinetics of N1/3-I5 with that of Nicotine Inhaler 10 mg, this study will have a multiple-dose setting. A crossover design has been chosen for this study in order to allow within-subject comparisons of treatments. Healthy habituated adults smoking at least 10 cigarettes daily for at least one year preceding inclusion will be included in the study, since they are expected to tolerate the doses of nicotine that will be administered.
A Japanese female in her twenties developed general edema with heavy proteinuria, and was referred to our hospital. She exhibited the common clinical manifestation of idiopathic nephrotic syndrome with massive proteinuria (20.37 g/day), hypoalbuminemia (1.8 g/dL), and hypercholesterolemia (300 mg/dL). Routine admission tests were positive results for both the rapid plasma reagin latex agglutination test for syphilis (RPR) and the Treponema pallidum particle agglutination assay (TPHA). As such, we made her a diagnosis of nephrotic syndrome due to secondary syphilis. Renal biopsy revealed "full-house" nephropathy. Following the commencement of penicillin treatment, she developed skin rash, indicating the Jarisch-Herxheimer reaction (JHR). Her nephrotic syndrome responded rapidly and she achieved complete remission with antibiotic therapy alone after 4 weeks. In light of the increasing incidence of syphilis in Japan, clinicians should consider syphilis as a reversible cause of nephrotic syndrome.
A method for preparing multivalent proteosomeamphiphilic determinant vaccines suitable for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiplilic determinants include lipopolysaccharides from gram negative bacteria, e.g.  S. flexneri, P. shigelloides  and  S. sonnei.  Proteosomes are obtained from group B type 2b meningococci. The active proteosomeamphiphilic determinant complexes (noncovalently complexes) of the vaccine are formed using defiltration or ultrafiltration to remove the detergent. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scaleup. In addition, the process permits the reliable and continuous monitoring of the dialysate which enhances the efficiency of the entire process. The time of dialysis for production of a lot of vaccine is reduced from 710 days to less than 72 hours and usually less than 48 or 4 hours. The use of the process optimizes the presence of each antigenic component in the preparation of multivalent vaccines.
PURPOSE: This study uses free-floating contractile fibroblast-populated collagen matrices (FPCMs) to test the shrinkage of different hernia mesh products. We hope to present this model as a proof of concept for the development of in vitro hernia mesh testing-a novel technology with interesting potential.
METHODS: FPCMs were formed by seeding Human Dermal Fibroblasts into collagen gels. FPCMs were seeded with three different cell densities and cast at a volume of 500 μl into 24-well plates. Five different mesh products were embedded within the collagen constructs. Gels were left to float freely within culture media and contract over 5 days. Photographs were taken daily and the area of the collagen gel and mesh were measured. Media samples were taken at days 2 and 4 for the purposes of measuring MMP-9 release. After 5 days, dehydrated FPCMs were also examined under light and fluorescence microscopy to assess cell morphology.
RESULTS: Two mesh products-the mosquito net and large pore lightweight mesh were found to shrink notably more than others. This pattern persisted across all three cell densities. There were no appreciable differences observed in MMP-9 release between products.
CONCLUSIONS: This study has successfully demonstrated that commercial mesh products can be successfully integrated into free-floating contractile FPCMs. Not only this, but FPCMs are capable of applying a contractile force upon those mesh products-eliciting different levels of contraction between mesh products. Such findings demonstrate this technique as a useful proof of concept for future development of in vitro hernia mesh testing.
The present invention relates to the technical field of gene therapy, and in particular, to a nucleic acid construct for treating hereditary coagulation factor deficiency and a novel use thereof. The construct comprises the following elements: a polynucleotide encoding coagulation factor IX; and an AAV cis-regulatory element comprising one or more of an ITR, a promoter, a kozak sequence, an SV40 polyA, a UTR, or a WPRE. Preferably, the sequence of the polynucleotide encoding coagulation factor IX is a sequence that has undergone codon optimization. Preferably, the polynucleotide sequence that has undergone codon optimization is a sequence of coagulation factor IX comprising an R338L mutation. The novel use is use of an AAV vector serotype targeting muscle in preparing a hereditary coagulation factor deficiency therapeutic product. An adeno-associated virus prepared from the nucleic acid construct and a nucleic acid construct carrying a coagulation factor target gene may have a muscle targeting property in an intramuscular injection delivery mode, and help express the coagulation factor at a therapeutically effective amount.
The present invention relates to a human body health-care product, particularly to a health-care product containing lindera root, etc. and a manufacturing method. The present invention aims to provide the health-care product which is prepared by compounding lindera root, solomonseal rhizome and American ginseng as main ingredients, and other health raw materials, and the health-care product has the advantages of convenient drinking and immunoregulation improvement so as to be convenient for the drinking of people. The present invention also aims to provide the manufacturing method for the health-care product. When drunk regularly, the product has immunoregulation effect on a human body, and the product is particularly suitable for yin deficiency, essence deficiency, thirst, dry throat, heat vexation in the five hearts, rotten lip, toothache, lassitude of the spirit, dry cough, limp aching lumbus and knees, a person with the symptoms occurring after cancer chemoradiotherapy, and a person who has malaise caused by smoking, spirits, night life, overwork and subhealth. The health-care product can regulate the vitality of the spleen and the stomach in the upper part and restore the kidney channel of Shaoyin so as to overcome adverse reaction caused by taking single medicinal raw material, and the health-care product is convenient to carry, is favorable for storage, and is convenient to drink.
Hospital-acquired conditions in the United States are considered avoidable complications but remain common statistics reflecting on health system performance and are a leading cause of patient fatality. Currently, over 3.7 million patients experience a hospital-acquired condition in the United States each year, which costs the U.S. healthcare delivery system an excess of $48 billion. Evidence-based clinical practice guidelines for common hospital-acquired conditions (e.g., infections, falls, pressure injuries) to reduce risk to the patient. In each of these instances, preventing the outcome with these guidelines costs less than treating the outcome, in addition to keeping the patient safe from harm. By applying the framework of defects in value to hospital-acquired conditions, we estimate that U.S. health systems could avert this $48 billion in spending on treating harmful hospital-acquired conditions; more so, these systems of care could recuperate over $35 billion after investing proportionally in a system that delivers greater quality by preventing hospital-acquired conditions over treating them. Currently, the Centers for Medicare and Medicaid Services only withholds reimbursements for hospital-acquired conditions and penalizes health systems with high rates of these outcomes. However, payers do not offer any reward-based incentives for hospital-acquired condition prevention. A series of policy and health system solutions, including tracking of hospital-acquired condition rates in electronic health records, identifying centers of excellence at reducing rates of harm with the use of clinical practice guidelines, and rewarding them monetarily for reduced rates could create equal-sided risk and opportunity to engage health systems in improved performance.
Intussusception is defined as the invagination of a proximal segment of the bowel into the adjoining or distal segment. In most adults with intussusception, there is a demonstrable lead point with a definite pathologic abnormality. The clinical features of intussusception include chronic intermittent abdominal pain, nausea and vomiting, constipation, and a palpable abdominal mass. The present case report describes a 62-year-old woman with a 2-week history of abdominal pain and 9-day history of vomiting. Clinical, imaging, and histologic evaluations revealed a jejunojejunal intussusception with a gastrointestinal stromal tumor as the lead point. A gastrointestinal stromal tumor should be considered as a possible lead point in adult patients with intussusception. The implication of reducing the intussusception prior to tumor resection requires further evaluation in view of the risk of venous embolism, including direct spread of malignant cells, in cases involving a large polypoid mass with a necrotic surface that extends to the serosa as shown by intraoperative examination. Accordingly, the rationale for adjuvant therapy with imatinib also requires further evaluation.
PURPOSE: Preoperative anemia increases postoperative morbidity, mortality, and the risk of allogeneic transfusion. However, the incidence of preoperative anemia in patients undergoing total hip arthroplasty and total knee arthroplasty (TKA) and its relationship to postoperative outcomes has not been previously reported.
METHODS: We conducted a comprehensive literature search through PubMed, Cochrane Library, Web of Sincien, and Embase from inception to July 2023 to investigate the prevalence of preoperative anemia in patients undergoing Total Joint Arthroplasty, comorbidities between anemic and non-anemicpatients before surgery, and postoperative outcomes. postoperative outcomes were analyzed. Overall prevalence was calculated using a random-effects model, and heterogeneity between studies was examined by Cochran's Q test and quantified by the I2 statistic. Subgroup analyses and meta-regression analyses were performed to identify sources of heterogeneity. Publication bias was assessed by funnel plots and validated by Egger's test.
RESULTS: A total of 21 studies with 369,101 samples were included, all of which were retrospective cohort studies. 3 studies were of high quality and 18 studies were of moderate quality. The results showed that the prevalence of preoperative anemia was 22% in patients awaiting arthroplasty; subgroup analyses revealed that the prevalence of preoperative anemia was highest in patients awaiting revision of total knee arthroplasty; the highest prevalence of preoperative anemia was found in the Americas; preoperative anemia was more prevalent in the female than in the male population; and preoperative anemia with a history of preoperative anemia was more common in the female than in the male population. patients with a history of preoperative anemia; patients with joint replacement who had a history of preoperative anemia had an increased risk of infection, postoperative blood transfusion rate, postoperative blood transfusion, Deep vein thrombosis of the lower limbs, days in hospital, readmission within three months, and mortality compared with patients who did not have preoperative anemia.
CONCLUSION: The prevalence of preoperative anemia in patients awaiting total joint arthroplasty is 22%, and is higher in TKA and female patients undergoing revision, while preoperative anemia is detrimental to the patient's postoperative recovery and will increase the risk of postoperative complications, transfusion rates, days in the hospital, readmission rates, and mortality.
An oil-in-water emulsion composition comprising 1-9 wt% of an emollient; 2-20 wt% of a humectant; 0.1-5 wt% of a cooling agent selected from menthol, menthyl lactate, menthyl acetate, levomenthol, one or more menthol esters, and methydiisopropyl propionamide; 0.2-10 wt% of an anti-inflammatory agent comprising dimethyl sulfone (methylsulfonylmethane, MSM); 5-10 wt% of an emulsifier; and 60-75 wt% water is provided. The emollient may be selected from at least one of mineral oil, petrolatum, paraffin, ozokerite, microcrystalline wax, polyethylene, squalene and perhydrosqualene. The emulsifier may be selected from polyethylene glycol ethers, polyglyceryl fatty acid esters, and an acrylate-C10-30 acrylate crosspolymer, particularly polyethylene glycol ethers of isocetyl alcohol, isostearyl alcohol, cetyl alcohol, oleyl alcohol and cetearyl alcohol. The composition may further comprise a preservative and/or a pH modifier. A method for moisturising the skin of a subject using the composition is also provided, comprising spraying the composition onto a garment and applying the garment to the skin of the subject. A garment comprising the moisturising composition is also provided. The garment may comprise an inner and outer layer, wherein the inner layer may comprise a polyamide material such as nylon 66, or a knitted yarn.
During this visit, subjects will perform a 6-min treadmill exercise wearing an oronasal mask connected (through a hose) with a three-way valve to an altitude simulation device (Altitrainer; SMTech, Nyon, Switzerland). For the exercise performed in normoxia conditions, subjects will breathe room air.
Disclosed herein are methods of treating a brain cancer comprising administering to a subject in need thereof a viral composition comprising a flavivirus or portion of a flavivirus wherein the flavivirus is engineered to comprise a heterologous nucleic acid sequence encoding a suicide gene. In some embodiments, the brain cancer is selected from the group consisting of astrocytoma, oligodendroglioma, ependymoma, meningioma, schwannoma, craniopharyngioma, germinoma, and pineocytoma. In some embodiments the flavivirus comprises Zika virus, spondweni virus, kedougous virus, or a combination thereof. In some embodiments, the flavivirus comprises Zika virus. In some embodiments, the suicide gene encodes a protein that converts a prodrug into a cytotoxic agent. In some embodiments, the viral composition is administered in combination with the immunostimulatory agent.
PURPOSE:To provide a fat emulsion containing a biphenylylpropionic acid derivative obtained by the esterification of flurbiprofen, free from stimulation and having excellent analgesic, antiinflammatory and antipyretic activities compared with a flurbiprofen preparation and low side effects. CONSTITUTION:The objective fat emulsion contains one or more biphenylylpropionic acid derivatives of formula I [R is group of formula II (R1 is H, 1-3C lower alkyl, etc.; R2 is 1-15C alkyl or 2-8C alkenyl; m is 0 or 1) or formula III(R3-4 are H or lower alkyl; n is 1-2)]. Preferably, the emulsion contains 0.01- 30% (W/V) of the compound of formula I , 5-50% (W/V) of soybean oil, 1- 5pts.wt. (based on 100pts. of soybean oil) of a phospholipid, and a proper amount of water. It has high oleophilic property, exhibits remarkable drug action for a long period at a low dose. It is non-irritant and can be administered by intravenous injection. Useful for the analgesic and anti-inflammatory treatment of chronic articular rheumatism, lumbago, etc.
The use of a monocarboxylate transporter protein or a functional part, derivative and/or analogue thereof for altering transport of a thyroid hormone or a functional part, derivative and/or analogue thereof across a membrane. The monocarboxylate transporter protein preferably comprises MCT-8. An isolated molecule capable of specifically binding at least part of an MCT protein, at least part of a ligand of an MCT protein, or a nucleic acid encoding the MCT and/or ligand, is also herewith provided. Regulation of the bioavailability of thyroid hormone in a tissue enables interfering with diseases. The invention also provides pharmaceutical compositions comprising a compound capable of binding the MCT protein or capable of influencing the binding or transporting of a ligand of the MCT protein. Methods for diagnosis and/or treatment of a disease, such as a disorder of thyroid metabolism, non-thyroidal illness, obesity or cardiovascular illness, are also provided, as well as bioassays for identifying or detecting a candidate drug capable of binding to, or influencing at least part of, the MCT protein.
Ataxia-ocular apraxia 2 (AOA2) is a rare neurodegenerative autosomal recessive disorder with no effective treatment. In this study, we present the case of a patient diagnosed with AOA2, who experienced walking instability and uncoordinated movement. The patient underwent transcranial alternating current stimulation (tACS) treatment for 4 weeks with follow-up after 1 month. The effectiveness of the treatment was evaluated using the International Cooperative Ataxia Rating Scale (ICARS), the Scale for the Assessment and Rating of Ataxia (SARA), the 9-Hole Peg Test (9HPT), and functional near-infrared spectroscopy (fNIRS). Following treatment, the patient's ataxia symptoms showed significant improvement and continued to be alleviated during the follow-up period, suggesting a lasting effect of tACS treatment. Our findings from this case study provide compelling evidence for the potential of tACS as a treatment option for AOA2.
OBJECTIVES: The aim of this economic analysis was to evaluate the cost-effectiveness of differential target multiplexed spinal cord stimulation (DTM-SCS) for treating chronic intractable low back pain, compared with conventional spinal cord stimulation (C-SCS) and conservative medical management (CMM), by updating and expanding the inputs for a previously published cross-industry model.
MATERIALS AND METHODS: This model comprised a 12-month decision-tree phase followed by a long-term Markov model. Costs and outcomes were calculated from a UK National Health Service perspective, over a base-case horizon of 15 years and up to a maximum of 40 years. All model inputs were derived from published literature or other deidentified sources and updated to reflect recent clinical trials and costs. Deterministic and one-way sensitivity analyses were performed to calculate costs and quality-adjusted life-years (QALYs) across the 15-year time horizon and to explore the impact of individual parameter variability on the cost-effectiveness results. Probabilistic sensitivity analysis was undertaken to explore the impact of joint parameter uncertainty on the results.
RESULTS: DTM-SCS was the most cost-effective option from a payer perspective. Compared with CMM alone, DTM-SCS was associated with an incremental cost-effectiveness ratio (ICER) of £6101 per QALY gained (incremental net benefit [INB] = £21,281). The INB for C-SCS compared with CMM was lower than for DTM-SCS, at £8551. For the comparison of DTM-SCS and C-SCS, an ICER of £897 per QALY gained was calculated, with a 99.5% probability of cost-effectiveness at a £20,000 per QALY threshold.
CONCLUSIONS: Among patients with low back pain treated over a 15-year follow-up period, DTM-SCS and C-SCS are cost-effective compared with CMM, from both payer and societal perspectives. DTM-SCS is associated with a lower ICER than that of C-SCS. Wider uptake of DTM-SCS in the UK health care system is warranted to manage chronic low back pain.
Participants will be following the Specific Carbohydrate Diet (SCD). Allowed foods include meat/fish/poultry, eggs, some legumes (e.g., lentils and split peas are permitted, chickpeas and soybeans are not), fully fermented yogurt, non-starchy vegetables, ripe fruit, nuts/seeds, honey and nut flours (e.g. almond flour or coconut flour). Restricted foods include all grains, milk products aside from 24-hour fermented SCD yogurt and cheeses aged greater than 30 days, starchy vegetables, processed foods with food additives and sweeteners other than honey.